

Review Article

Was Antiphospholipid Syndrome a Risk Factor of Stroke? A Systemic Review and Meta-Analysis of Cohort Studies

Kai Zhao,¹ Ping Zhou,² Ling Xu,³ Ruili Li,⁴ Jincui Yang,¹ Qiang Zhang,² Mingfei Yang ²,
and Xiaoxing Wei ⁵

¹Graduate School, Qinghai University, Xining, Qinghai 810016, China

²Department of Neurosurgery, Qinghai Provincial People's Hospital, Xining, Qinghai 810007, China

³Department of Community Health Education, Institute for Health Education of Qinghai Province, Xining, Qinghai 810000, China

⁴Department of Neurological Intensive Care, Shengli Oilfield Central Hospital, Dongying, Shandong 257000, China

⁵Medical College of Qinghai University, Xining, Qinghai 810016, China

Correspondence should be addressed to Mingfei Yang; iloveyoucmu@163.com and Xiaoxing Wei; weixiaoxing@qhu.edu.cn

Received 25 August 2021; Accepted 25 November 2021; Published 16 December 2021

Academic Editor: Yuzhen Xu

Copyright © 2021 Kai Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Antiphospholipid syndrome (APS) is characterized by thrombosis. This systemic review and meta-analysis was to verify the hypothesis that APS might increase the risk of stroke. Studies were identified after literature searching of PubMed, Embase, and Cochrane. Newcastle-Ottawa Quality Assessment Scale Cohort Studies (NOQAS-C) was used to assess the quality of studies. The pooled effect with 95% confidence interval (95% CI) was calculated by random-effect model. *I*-square (*I*²) was used to test heterogeneity. Funnel plot was used to evaluate publication bias. A total of 17 cohort studies with overall high quality were included. There was no publication bias. Pooled hazard ratio of stroke occurrence in APS patients was 1.76 (1.39-2.21) with low heterogeneity and stable result from sensitivity analysis. In the analysis of subgroups, pooled risk ratios of stroke occurrence in patients with only positive antibodies of APS diagnosis were 1.75 (0.99-3.09), which for the APS patients with other autoimmune diseases were 14.70 (7.56-28.56). APS might be a risk factor of stroke, especially in patients with other autoimmune diseases.

1. Introduction

Antiphospholipid syndrome (APS) is a disease characterized by recurrent arterial or venous thrombosis, pathological pregnancy, and consistently positive antiphospholipid antibodies (such as lupus anticoagulant laC, anticardiolipin antibody aCA, and anti- β_2 GP1 antibody a β A) [1]. APS could not only be secondary to the systemic lupus erythematosus (SLE) or other autoimmune diseases but also occur alone (known as primary APS (PAPS)) [2]. The incidence of APS is significantly higher in females than in males, and in particular, some females first find APS when they discover the causes of spontaneous miscarriage [3]. Due to consistently positive antiphospholipid antibodies, the abnormal coagulation function and vascular endothelial injury could bring about thrombosis events in many organs, leading to stroke, myocardial infarction, limb ischemia, and so on [4].

In addition to ischemic stroke (ISS), the platelet reduction can also appear in APS patients, which could be associated to hemorrhagic diseases, including the pulmonary alveolar hemorrhage and the intracranial hemorrhage (ICH) [5, 6]. However, in evidence-based medicine, there is still no convincing evidence supporting that APS increases the risk of stroke. Moreover, it is of great significance to find out whether patients with only positive antibody of APS diagnosis would face the onset risk. Therefore, this systemic review and meta-analysis based on cohort studies was performed to verify the hypothesis that APS might be the risk factor of stroke.

2. Methods

This systemic review and meta-analysis was performed referring to the protocol published on the database of




FIGURE 1: Process of literature search.

International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY, <https://inplasy.com/>, registration number: INPLASY202180074, DOI number: 10.37766/inplasy2021.8.0074).

2.1. Data Sources. Literature searching was performed in three public electronic databases of PubMed, Embase, and Cochrane. The strategy of literature searching was as follows: (((((((((((((((((((("Stroke"/exp) OR ("Stroke*":ab,ti)) OR ("Cerebrovascular Disease*":ab,ti)) OR ("CVA* (Cerebrovascular Accident)":ab,ti)) OR ("Cerebrovascular Apoplexy":ab,ti)) OR ("Apoplexy, Cerebrovascular":ab,ti)) OR ("Vascular Accident, Brain":ab,ti)) OR ("Brain Vascular Accident*":ab,ti)) OR ("Vascular Accidents, Brain":ab,ti)) OR ("Cerebrovascular Stroke*":ab,ti)) OR ("Stroke*, Cerebrovascular":ab,ti)) OR ("Apoplexy":ab,ti)) OR ("Cerebral Stroke*":ab,ti)) OR ("Stroke*, Cerebral":ab,ti)) OR ("Stroke, Acute":ab,ti)) OR ("Acute Stroke*":ab,ti)) OR ("Strokes, Acute":ab,ti)) OR ("Cerebrovascular Accident*, Acute":ab,ti)) OR ("Acute Cerebrovascular Accident*":ab,ti)) AND (((((((((((((((((((("Antiphospholipid Syndrome"/exp) OR ("Syndrome, Antiphospholipid":ab,ti)) OR ("Hughes Syndrome":ab,ti)) OR ("Syndrome, Hughes":ab,ti)) OR ("Antiphospholipid Antibody Syndrome":ab,ti)) OR ("Antibody Syndrome, Antiphospholipid":ab,ti)) OR ("Antiphospholipid Antibody Syndromes":ab,ti)) OR ("Syndrome, Antiphospholipid Antibody":ab,ti)) OR ("Anti-Phospholipid Antibody Syndrome":ab,ti)) OR ("Anti Phospholipid Antibody Syndrome":ab,ti)) OR ("Antibody Syndrome, Anti-Phospholipid":ab,ti)) OR ("Syndrome, Anti-Phospholipid Antibody":ab,ti)) OR ("Anti-Phospholipid Syndrome":ab,ti)) OR ("Anti Phospholipid Syndrome":ab,ti)) OR ("Syndrome, Anti-Phospholipid":ab,ti)).

2.2. Study Selection. Inclusion criteria are as follows: (1) language, regions, and publication years of articles were not restricted; (2) cohort studies; (3) participants in the exposure group suffered from APS; (4) participants in the nonexpos-

ure group only differed in no APS suffering; (5) endpoint of observation was stroke; and (6) analysis of cohort studies' outcomes was completely performed. Exclusion criteria are as follows: (1) duplication; (2) reviews, comments, letters, case reports, protocols of clinic trials, or conference papers; (3) animal experiments; and (4) contents of articles were irrelevant to this meta-analysis.

2.3. Quality Assessment of Studies. The quality assessment of included articles was performed via the Newcastle-Ottawa Quality Assessment Scale Cohort Studies (NOQAS-C) before data extraction. We considered that the studies with larger size of included patients should be assessed to have higher quality, in accordance with the results from the NOQAS-C assessment.

2.4. Data Extraction. All data used to assess the outcomes of these cohort studies were extracted, including the hazard ratio (HR), risk ratio (RR), and odds ratio (OR). In addition, some confounders, which might result in errors, were adjusted, including the ages, gender, accompanying conditions of participation before study, definition of endpoint, and period of observation.

2.5. Statistical Methods. Relative numbers and their 95% confidence intervals (95% CI) were used to describe the count data. Meta-analysis was performed using corresponding modules with the Software for Statistics and Data Science (Stata, version 15.1; College Station, Texas 77845 USA). The pooled effect with its 95% CI was calculated by the random-effect model. The I^2 was used to test the heterogeneity. Sensitivity analysis was performed to evaluate the stability of the overall results by recalculating the pooled effects of the remaining studies after omitting the highest-quality study, or the random-effect model was switched to the fixed-effect model. Funnel plot symmetry or Egger's regression was used to evaluate the publication bias. To reduce heterogeneity, the pooled effects of the

TABLE 1: Characteristics of included studies.

Publication year	The first author	Countries or regions	Mean ages (SD)	Male/total participation	Other concomitant characteristics of participation before study	Period of observation (years)	Endpoint of observation
1993	Robert M. Silver	United States of America	31 (2)	19/130	N/A	10	Stroke
2002	A. Blohorn	France	37.2 (7)	69/139	2 subgroups of positive antibody types ^a	5	Stroke
2009	Kumar Rajamani	United States of America	59.2 (12.1)	292/545	Heart disease related to autoimmunity ^b	2	Stroke
2012	Marcello Govoni	Italy	46.2 (14.8)	51/469	SLE	10	Stroke
2013	Chi Chiu Mok	Hong Kong (China)	32.5 (14)	51/679	SLE	7	Stroke
2014	P. Mustonen	Finland	44.7 (14.3)	13/119	3 subgroups of positive antibody types	38	Stroke
2014	R. Cervera	Spain	42 (14)	180/552	SLE	10	Stroke
2016	Jean-Christophe Gris	France	30 (5)	0/1313	Gestation	10	TIA, ISS ^c
2018	Radin Massimo	Italy	43.4 (10.4)	5/36	4 subgroups of positive antibody types	2	Stroke
2018	Serena Fasano	Italy	37 (12.2)	17/297	2 subgroups of positive antibody types	7	Stroke
2019	Daniel Bertin	France	45 (18)	162/442	3 subgroups of positive antibody types	6	Stroke
2019	Kanon Jatuworapruk	Thailand	41.6 (17.3)	24/74	N/A	5	Stroke
2019	Maryam Sahebari	Iran	19.6 (12.46)	25/205	3 subgroups of positive antibody types	3	Stroke
2020	Aline G. Islabão	Brazil	12 (6)	231/1519	No adults	15	Stroke
2020	Stylianios Panopoulos	Greece	48.7 (13.4)	136/495	RA, SLE	14	Stroke
2021	Elise Danielle McVeigh	United States of America	38 (11.97)	9/80	SLE	17	Stroke
2021	Safífa Bano	Pakistan	28.39 (7.19)	5/50	N/A	3	Stroke

SD: standard deviation; SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; TIA: transient ischemic attack; ISS: ischemic stroke. ^aAPS diagnosis was absolutely dependent on different types of positive antibodies, which meant APS patients were separated to single positive antibody group such as laC(+), aCA(+), and aβA(+); double positive antibody group such as laC/aCA(+), aCA/aβA(+), and laC/aβA(+); and triple positive antibody group. ^bApart from APS, other autoimmune diseases appeared on participation. ^cStroke was separated to different types: TIA, ISS, and others.

remaining studies would be recalculated after omitting the lowest-quality study, or the subgroup analysis was performed directly. All *p* values were two-sided with a significant level at 0.05.

3. Results

3.1. Selection. In total, 2767 articles were retrieved from the databases according to the study strategy. After screening based on the inclusion and exclusion criteria, 17 cohort studies [7–23] were enrolled ultimately (Figure 1). There were a total of 7144 people participating in all these studies, including 1289 males (Table 1). The age range was 6 to 72 years old. Countries or regions involved Asia, America, and Europe. Publication years were from 1993 to 2021,

including all the cohort studies in the 21st century. Periods of observation were from 2 to 38 years. There were also other concomitant characters of participation before studies, which might influence results of our meta-analysis. These confounding factors could be divided into 3 major groups: (1) none; (2) other concomitant autoimmune diseases, including SLE, rheumatoid arthritis (RA), and related organ injuries (such as heart injuries); and (3) APS diagnosis absolutely depended on different types of positive antibodies, which meant that the APS patients were divided into the following: (1) the single positive antibody groups, such as laC(+), aCA(+), and aβA(+); (2) double positive antibody group, such as laC/aCA(+), aCA/aβA(+), and laC/aβA(+); and (3) triple positive antibody group. In addition, one study defined the endpoint that patients suffered from transient

TABLE 2: Quality assessment of included studies via Newcastle-Ottawa Quality Assessment Scale Cohort Studies.

Year	Authors	Selection				Comparability	Assessment	Outcome		Total
		Representative	Nonexposed	Ascertainment	Not present			Long enough	Adequacy	
1993	Robert M. Silver	*	*	*	*	*	*	*		7
2002	A. Blohorn	*	*	*	*	*	*	*		7
2009	Kumar Rajamani	*	*	*	*	**	*		*	8
2012	Marcello Govoni	*	*	*	*	*	*	*		7
2013	Chi Chiu Mok	*	*	*	*	**	*	*	*	9
2014	P. Mustonen	*	*	*	*	**	*	*		8
2014	R. Cervera	*	*	*		**	*	*	*	8
2016	Jean-Christophe Gris	*		*		**	*	*		6
2018	Radin Massimo	*		*		**	*		*	6
2018	Serena Fasano	*	*	*	*	**	*	*	*	9
2019	Daniel Bertin	*		*	*	*	*	*		6
2019	Kanon Jatuworapruk	*	*	*		**	*	*		7
2019	Maryam Sahebari	*	*	*	*	*	*		*	7
2020	Aline G. Islabão	*	*	*	*	**	*	*	*	9
2020	Stylianios Panopoulos	*	*	*		**	*	*		7
2021	Elise Danielle McVeigh	*	*	*		**	*	*		7
2021	Safífa Bano	*	*	*	*	**	*		*	8

ischemic attack (TIA) or ISS, which were subtypes of stroke. Therefore, considering these factors, different data might be extracted from the same article.

3.2. Comparability. According to NOQAS-C, three studies (2018Serena Fasano, 2013Chi Chiu Mok, and 2020Aline G. Islabão) were scored as 9, which was the highest score (Table 2). In the Selection section, three articles were assessed to be with high risk of the nonexposed segment, and six articles were assessed to be with high risk of the not present segment. Five articles were assessed to be with risk in the Comparability section. In the Outcome section, 4 articles were assessed to be with high risk of the long enough segment, and 9 articles were assessed to be with high risk of the adequacy segment. Finally, 3 articles were scored as 6 (2016Jean-Christophe Gris, 2018Radin Massimo, and 2019Kanon Jatuworapruk), which was the lowest score.

3.3. Outcome. Totally pooled HR, RR, and OR were 1.76 (1.39-2.21), 2.29 (0.81-6.44), and 3.25 (1.60-6.61), respectively. Heterogenicities of totally pooled HR, RR, and OR were 0.0% ($p = 0.547$), 88.3% ($p < 0.001$), and 93.3% ($p < 0.001$), respectively (Figure 2). In sensibility analysis, after omitting the highest-quality study, the pooled HR

(2018Serena Fasano), RR (2013Chi Chiu Mok), and OR (2020Aline G. Islabão) were 1.63 (1.27-2.10), 1.52 (0.97-2.38), and 2.69 (1.44-5.03), respectively. Heterogenicities of pooled HR, RR, and OR in the sensibility analysis were 0.0%, 27.8%, and 90.7%, respectively (Table 3). There were symmetrical distributions in the funnel plots of HR, RR, and OR (Figure 3). The high heterogenicities of totally pooled RR and OR might be a reason for the study's lowest quality. In the meta-analysis, after omitting those studies of HR (2016Jean-Christophe Gris), RR (2018Radin Massimo), and OR (2019Kanon Jatuworapruk), the pooled effects were 1.73 (1.13-2.63), 2.78 (0.52-14.86), and 3.32 (1.58-6.96), respectively, with still high heterogenicities, i.e., 32.5%, 92.7%, and 93.7% (Table 3), respectively. Referring to other concomitant characters of participation before studies, the subgroup analysis was performed for crude, antibody, and autoimmune in totally pooled RR and OR (Figure 4). In the subgroup analysis, the totally pooled RRs of antibody and autoimmune were 1.75 (0.99, 3.09) and 12.29 (0.18~848.28), with the heterogenicities of 29.5% ($p = 0.203$) and 97.9% ($p < 0.001$), respectively. Moreover, the totally pooled ORs of crude, antibody, and Autoimmune were 1.92 (1.09, 3.37), 0.82 (0.61-1.11), and 14.70 (7.56-28.56), with the heterogenicities of 0.0% ($p = 0.687$), 29.3% ($p = 0.195$), and 78.2% ($p < 0.001$), respectively.




FIGURE 2: Totally pooled HR/RR/OR.

TABLE 3: Sensibility analysis of totally pooled HR/RR/OR.

Modification	I^2 , HR (95% CI) (study ID)	I^2 , RR (95% CI) (study ID)	I^2 , OR (95% CI) (study ID)
	$I^2 = 0.0\%$	$I^2 = 27.8\%$	$I^2 = 90.7\%$
The study with the highest quality omitted	1.63 (1.27~2.10) (2018Serena Fasano)	1.52 (0.97~2.38) (2013Chi Chiu Mok)	2.69 (1.44~5.03) (2020Aline G. Isiabão)
	$I^2 = 32.5\%$	$I^2 = 92.7\%$	$I^2 = 93.7\%$
The study with the lowest quality omitted	1.73 (1.13~2.63) (2016Jean-Christophe Gris)	2.78 (0.52~14.86) (2018Radin Massimo)	3.32 (1.58~6.96) (2019Kanon Jatuworapruk)

4. Discussion

Cohort studies published in the 21st century were selected herein to perform a systemic review and meta-analysis, crossing continents and involving all age and gender groups. According to definition in clinical epidemiology, HR and RR have higher qualities of explaining causal relationship, com-

pared with OR. Moreover, time factor is involved in HR, which is an advantage of HR compared with RR [24, 25]. In our meta-analysis, the totally pooled HR supported that APS was a risk factor of stroke with low heterogeneity and a stable result of sensibility analysis. Yet the totally pooled RR showed that APS could not increase occurrence of stroke with high heterogeneity and a stable result of sensibility




FIGURE 3: Funnel plots of totally pooled HR/RR/OR.

analysis. Totally pooled OR transmitted the same conclusion of HR with high heterogeneity and a stable result of sensibility analysis. In the subgroup analysis of totally pooled RR and OR, they both showed that the APS diagnosis absolutely based on positive antiphospholipid antibodies could not increase stroke occurrence with low heterogeneity. We considered that in patients with a purely positive antibody, who might have no characteristics in the clinic, the immune tolerance and immune response were under a balanced condition of a relatively lower sensitized immune system [26, 27]. Subgroup analysis of OR transmitted that APS patients with other concomitant autoimmune diseases or related organ injuries would have risk of stroke. Although RR had the advantage of explaining the causal relationship compared with OR, the results from the autoimmune subgroup analysis of RR with more significant heterogeneity (only enrolling two studies) might have the lower quality of evidence. In addition, the subgroup analysis of OR also showed that patients without confounding factors had risk of stroke. We considered that previous organ injuries could not only expose the location of immunologic injury via PAPS but also enlarge the injury effect of primary diseases in secondary APS via other autoimmune diseases [28, 29].

High heterogeneities represent the major limits of this study, especially for totally pooled RR and OR. However, publication bias and the lowest-quality study might not be the reason. On the contrary, omitting the study with the highest quality could reduce the heterogeneity of pooled RR. Therefore, we supposed that in the 2006 classification criteria [30], an amendment was made to the levels of antibodies for the diagnosis of APS, which could make the phenomenon that APS patients included in studies before 2006 were different from those after 2006. In addition, some unknown confounders might potentially exist in this study, such as that the participants in the nonexposed groups might receive medical prevention of stroke. In the pooled OR, we supposed that the source of heterogeneity might be from the autoimmune subgroup, which included studies with different characters of patients before the study. In particular, one study included no adults, while another study included patients suffering from RF. In addition, stroke as the definition of the endpoint might cover a wide range. We could not be sure whether ICH appears in the endpoint. In the future, studies with larger numbers of participants, longer period of observation, and more detailed grouping or definition of the endpoint in





FIGURE 4: Subgroup analysis of RR/OR.

the cohort study are still needed to reduce the unknown confounders.

5. Conclusion

APS might be a risk factor of stroke, especially in patients with other autoimmune diseases. However, purely positive antiphospholipid antibodies might not increase the occurrence of stroke.

Conflicts of Interest

No potential conflict of interest was reported by the authors.

Authors' Contributions

Mingfei Yang and Kai Zhao conceived the idea and designed the study. Ling Xu and Ruili Li screened the studies and extracted the data independently. Jincui Yang and Qiang Zhang analyzed and interpreted the data. Kai Zhao and Ping Zhou wrote the first draft of the manuscript. Mingfei Yang and Xiaoxing Wei proofread the manuscript before submission. All authors reviewed the manuscript and approved the final version. Kai Zhao, Ping Zhou, and Ling Xu are co-first authors.

Acknowledgments

This work was funded by the Project of Science and Technology Department of Qinghai Province (No. 2020-ZJ-774).

References

- [1] D. Garcia and D. Erkan, "Diagnosis and management of the antiphospholipid syndrome," *The New England Journal of Medicine*, vol. 378, no. 21, pp. 2010–2021, 2018.
- [2] L. R. Sammaritano, "Antiphospholipid syndrome," *Best Practice & Research. Clinical Rheumatology*, vol. 34, no. 1, article 101463, 2020.
- [3] M. Petri, "Antiphospholipid syndrome," *Journal of Laboratory and Clinical Medicine*, vol. 225, pp. 70–81, 2020.
- [4] Z. Sayar, R. Moll, D. Isenberg, and H. Cohen, "Thrombotic antiphospholipid syndrome: a practical guide to diagnosis and management," *Thrombosis Research*, vol. 198, pp. 213–221, 2021.
- [5] E. Tsukamoto, T. Tanei, J. Senda et al., "Subarachnoid hemorrhage after ischemic stroke associated with systemic lupus erythematosus and antiphospholipid syndrome," *World Neurosurgery*, vol. 136, pp. 248–252, 2020.
- [6] P. Guraieb-Chahín, C. Cantú-Brito, A. Soto-Mota et al., "Stroke in systemic lupus erythematosus: epidemiology, mechanism, and long-term outcome," *Lupus*, vol. 29, no. 5, pp. 437–445, 2020.
- [7] R. M. Silver, M. L. Draper, J. R. Scott, J. L. Lyon, J. A. Reading, and D. W. Branch, "Clinical consequences of antiphospholipid antibodies: an historic cohort study," *Obstetrics and Gynecology*, vol. 83, no. 3, pp. 372–377, 1993.
- [8] A. Blohorn, E. Guegan-Massardier, A. Triquenot et al., "Antiphospholipid antibodies in the acute phase of cerebral ischaemia in young adults: a descriptive study of 139 patients," *Cerebrovascular Diseases*, vol. 13, no. 3, pp. 156–162, 2002.
- [9] K. Rajamani, S. Chaturvedi, Z. Jin et al., "Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events," *Stroke*, vol. 40, no. 7, pp. 2337–2342, 2009.
- [10] M. Govoni, S. Bombardieri, A. Bortoluzzi et al., "Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients," *Rheumatology*, vol. 51, no. 1, pp. 157–168, 2012.
- [11] C. C. Mok, P. T. Chan, L. Y. Ho, K. L. Yu, and C. H. To, "Prevalence of the antiphospholipid syndrome and its effect on survival in 679 Chinese patients with systemic lupus erythematosus," *Medicine*, vol. 92, no. 4, pp. 217–222, 2013.
- [12] P. Mustonen, K. V. Lehtonen, K. Javela, and M. Puurunen, "Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study," *Lupus*, vol. 23, no. 14, pp. 1468–1476, 2014.
- [13] R. Cervera, R. Serrano, G. J. Pons-Estel et al., "Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients," *Annals of the Rheumatic Diseases*, vol. 74, no. 6, pp. 1011–1018, 2015.
- [14] J. C. Gris, S. Bouvier, N. Molinari et al., "Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study," *Blood*, vol. 119, no. 11, pp. 2624–2632, 2016.
- [15] M. Radin, K. Schreiber, I. Cecchi, D. Roccatello, M. J. Cuadrado, and S. Sciascia, "The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study," *European Journal of Neurology*, vol. 25, no. 2, pp. 320–325, 2018.
- [16] S. Fasano, D. P. E. Margiotta, L. Pierro et al., "Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study," *Clinical Rheumatology*, vol. 38, no. 2, pp. 457–463, 2019.
- [17] D. Bertin, A. Beziane, N. Resseguier et al., "Interest of IgG and IgM antiprothrombin autoantibodies in the exploration of antiphospholipid syndrome: a 5-year retrospective study," *Rheumatology (Oxford, England)*, vol. 59, no. 7, pp. 1539–1544, 2019.
- [18] K. Jatuworapruk, L. Bhoopat, and P. Hanvivadhanakul, "Clinical and immunological characteristics of antiphospholipid syndrome in an Asian population: a retrospective study," *Asian Pacific Journal of Allergy and Immunology*, vol. 37, no. 3, pp. 171–178, 2019.
- [19] M. Sahebari, M. Rastin, R. Boostani, M. Foroughipour, K. Hashemzadeh, and S. H. Sadeghi, "Subtypes of antiphospholipid antibodies in neurologic disorders: an observational study," *Current Rheumatology Reviews*, vol. 15, no. 1, pp. 59–66, 2019.
- [20] A. G. Islabão, L. M. H. Mota, M. C. M. Ribeiro et al., "Childhood-onset systemic lupus erythematosus-related antiphospholipid syndrome: a multicenter study with 1519 patients," *Autoimmunity Reviews*, vol. 19, no. 12, article 102693, 2020.
- [21] S. Panopoulos, K. Thomas, G. Georgiopoulos et al., "Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control

- study,” *Rheumatology (Oxford, England)*, vol. 60, no. 1, pp. 170–178, 2021.
- [22] E. D. McVeigh, A. Batool, A. Stromberg, A. Abdel-Latif, and N. M. Kazzaz, “Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy—a tertiary centre experience in an Appalachian state,” *Science & Medicine*, vol. 8, no. 1, article e000467, 2021.
- [23] S. Bano, M. U. Farooq, S. Nazir et al., “Structural imaging characteristic, clinical features and risk factors of cerebral venous sinus thrombosis: a prospective cross-sectional analysis from a tertiary care hospital in Pakistan,” *Diagnostics*, vol. 11, no. 6, p. 958, 2021.
- [24] T. J. VanderWeele, “Optimal approximate conversions of odds ratios and hazard ratios to risk ratios,” *Biometrics*, vol. 76, no. 3, pp. 746–752, 2020.
- [25] J. Escrig-Sos, “On how to analyze the credibility of a clinical trial or meta-analysis whose main result is expressed in odds ratio, relative risk or hazard ratio,” *Cirugía Española*, vol. 78, no. 6, pp. 351–356, 2005.
- [26] D. E. Houghton and S. Moll, “Antiphospholipid antibodies,” *Vascular Medicine*, vol. 22, no. 6, pp. 545–550, 2017.
- [27] Y. Zhang, M. Xiao, S. Zhang et al., “Coagulopathy and antiphospholipid antibodies in patients with Covid-19,” *The New England Journal of Medicine*, vol. 382, no. 17, article e38, 2020.
- [28] N. Kello, L. E. Khoury, G. Marder, R. Furie, E. Zapantis, and D. L. Horowitz, “Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature,” *Seminars in Arthritis and Rheumatism*, vol. 49, no. 1, pp. 74–83, 2019.
- [29] E. Cavalli, A. Bramanti, R. Ciurleo et al., “Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: diagnostic and therapeutic perspectives (review),” *International Journal of Molecular Medicine*, vol. 46, no. 3, pp. 903–912, 2020.
- [30] S. Miyakis, M. D. Lockshin, T. Atsumi et al., “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS),” *Journal of Thrombosis and Haemostasis*, vol. 4, no. 2, pp. 295–306, 2006.